Oxford BioDynamics invited to join FNIH steering committee
Discovery and development of novel epigenetic biomarkers-focussed biotechnology company Oxford BioDynamics announced on Thursday that itself and Dr Claudio Carini, a member of company’s scientific advisory panel, had been invited to join the Foundation for the National Institutes of Health Biomarkers Consortium as a member of the Cancer, Inflammation & Immunity, and Neuroscience Steering Committees.
The AIM-traded firm said the Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH that endeavours to discover, develop, and seek regulatory approval for biological markers, known as biomarkers, to support new drug development, precision medicine, and medical diagnostics.
It said the Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by The Biomarkers Consortium, as well as overseeing each individual project under its purview.
The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit and advocacy organisations, the board explained.
Dr Carini had prior experience as a member of the FNIH Biomarkers Consortium Steering Committees, as well as having consulted and sat on many other distinguished international advisory boards and committees including the Medical Research Council, Innovative Medicine Initiative and the PML Consortium, it added.
“We are delighted that Claudio will be joining these prestigious biomarker committees,” said Oxford BioDynamics CEO Christian Hoyer Millar.
“The FNIH Biomarkers Consortium aims to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease, and this is a goal that is shared by Oxford BioDynamics.
“We believe that becoming a member of these important FNIH committees will be beneficial as we continue to progress towards our strategic aim of becoming the industry standard for epigenetic biomarker discovery.”